ClinicalTrials.gg
Not yet recruitingNCT06049030Updated Sep 26, 2023

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Phase 1 interventional study of HS-10516 in Renal Cell Carcinoma, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in ccRCC.

Read the detailed description

This is a Phase Ia/Ib open label multicenter study of HS-10516 in Chinese patients aged 18 years or older with advanced clear cell renal cell carcinoma who have failed or are unavailable/intolerant to standard of care. HS-10516 as a single agent, is administrated orally once daily. The aim of phase Ia, a dose escalation study, is to identify the MTD/MAD of HS-10516. The goal of Phase Ib, a dose expansion study, is to evaluate the safety, pharmacokinetics and antitumor efficacy of HS-10516.

02

Conditions studied

  • Renal Cell Carcinoma

Keywords

  • Advanced Clear Cell Renal Cell Carcinoma
  • Kidney Cancer
  • Renal Cancer
  • Recurrent Renal Cell Carcinoma
03

In context

Carcinoma, Renal Cell

2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

This study's planned enrollment of 190 is above the median of 43 across 1,567 interventional studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female from 18 to 75 year-old
  2. confirmed locally advanced or clear cell renal cell carcinoma whose standard treatment failed or proven unavailable or intolerant
  3. Has at least one non-CNS target lesion per RESIST v1.1
  4. Has an performance status of 0-1
  5. Has a of ≥ 12 weeks
  6. Should use adequate measures throughout the study
  7. Females subject must not be pregnant at screening
  8. Has the ability to understand and willingness to sign a written before the performance of the study

Exclusion criteria

Exclusion Criteria:

  1. Received or being received treatment as follows:

    1. Hypoxia-induced factor inhibitors
    2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of study treatment.
    3. Cytotoxic chemotherapeutic drugs, drugs or other systematic anti-tumor therapies within 3 weeks before the first dose of study treatment
    4. Colony-stimulating factors (CSFs) within 4 weeks before the first dose of study treatment
    5. Local radiotherapy within 2 weeks prior to the first dose of study treatment; more than 30% of bone marrow radiotherapy or large-area irradiation within 4 weeks before the first dose of study treatment.
    6. Major surgery within 4 weeks prior to the first dose of study treatment.
  2. Has a pulse oximetry reading less than 92% at screening, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
  3. Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy
  4. Has another or a history of another malignancy
  5. Has inadequate bone marrow reserve or organ dysfunction
  6. Has a bleeding events or tendency within 1 month prior to the first dose of study treatment
  7. Has severe infections within 4 weeks prior to the first dose of study treatment
  8. Has digestive system diseases may influencing ADME of study drug
  9. Has a history of severe reaction, or proven allergic to HS-10516 or its metabolics
  10. Has any disease or condition would compromise subject safety or interfere with study assessments by investigator's decision
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Phase Ia dose escalation

    Participants will be assigned to pre-specified dose level to identify the MTD/MAD of HS-10516.

    Drug: HS-10516

  • Experimental
    Phase Ib dose expansion arm

    Participants will be assigned to the recommended dose level determined in Phase Ia to evaluate the safety, pharmacokinetics and antitumor efficacy of HS-10516

    Drug: HS-10516

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ia: MTD/MAD of HS-10516

    Maximum Tolerated Dose or Maximum Acceptable Dose determined by the Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 35 days of dosing) in the Dose Escalation Phase

    Time frame: Approximately 2 months

  2. Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. ORR will be assessed by IRC.

    Time frame: Approximately 1 year

Secondary outcomes

  1. The Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

    Time frame: Approximately 2 years

  2. Observed maximum plasma concentration (Cmax) of HS-10516

    Cmax will be obtained following administration of the first dose of HS-10516 during first 2 cycles.

    Time frame: Approximately 2 months

  3. Time to reach maximum plasma concentration (Tmax) of HS-10516

    Tmax will be obtained following administration of the first dose of HS-10516 during first 2 cycles.

    Time frame: Approximately 2 months

  4. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-10516

    Area under the plasma concentration versus time curve from time zero to the last sampling time when the concentration was no less than the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Approximately 1 year

  5. ORR by investigators

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Approximately 1 year

  6. Disease Control Rate (DCR)

    DCR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) or a stable disease (SD) of 8 weeks or longer based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Approximately 1 year

  7. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.

    Time frame: Approximately 1 year

  8. Progression Free Survival (PFS)

    PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death.

    Time frame: Approximately 2 years

  9. Overall Survival (OS)

    OS defined as the time from the date the participant started study drug to death for any reason.

    Time frame: Approximately 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Sep 2024, 12 months later.

Of 138 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 12 months is below that.

Counting every sponsor, half of 220 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Sep 21, 2023
StartEst.
Sep 25, 2023
Primary completionEst.
Sep 25, 2024
CompletionEst.
Sep 25, 2025
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049030
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 25, 2023 (estimated)
Primary completion
Sep 25, 2024 (estimated)
Completion
Sep 25, 2025 (estimated)
Last update
Sep 26, 2023

Study contacts

Yun Chen
Contact
cheny22@hspharm.com
+86 18652105250
Jun Guo, M.D.
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HIF-2alpha Inhibitor HS-10516

Start the discussion